Key Takeaway: Nurix is advancing NX-1607, a first-in-class inhibitor targeting CBL-B for immuno-oncology. This innovative approach aims to enhance treatment options for cancer and autoimmune diseases. The company emphasizes its dedication to developing breakthrough therapies through novel scientific insights.
Price reaction · baseline $14.51 (2024-04-02T16:15:00.000Z) · hit during market hours · 3 other NRIX headline(s) in the window, move may be shared
day 0 close · peak
+2.4%
Market Sentiment Analysis
POSITIVE FACTORS
Introduction of NX-1607 as a first-in-class inhibitor.
Focus on immuno-oncology, a rapidly advancing field.
Commitment to translating scientific insights into therapies.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.
Filter by
Frequently Asked Questions
What is NX-1607?
NX-1607 is a first-in-class inhibitor targeting CBL-B for immuno-oncology.
What diseases does NX-1607 aim to treat?
NX-1607 aims to treat cancer and autoimmune diseases.
Who is developing NX-1607?
NX-1607 is being developed by Nurix.
What is the significance of CBL-B in immuno-oncology?
CBL-B is a target that plays a crucial role in regulating immune responses.